 "Pharma Stocks, Sun Pharma, Cadila, Cipla")
Shares of Cadila Healthcare surged 5 per cent to Rs 380 on the BSE on Friday after the company said its vaccine candidate for Covid-19 (ZyCoV-D) has received the permission from DGCI for human clinical trials.
In an exchange filing, the company said it has received the approval from Drug Controller General of India - Central Drugs Standard Control Organisation (DCGI-CDSCO) to initiate Phase I/II human clinical trials for its Covid-19 (plasmid DNA) vaccine. The company has completed preclinical development and plans to begin the trials in July 2020, it said.
In animal studies, the vaccine was found to
In an exchange filing, the company said it has received the approval from Drug Controller General of India - Central Drugs Standard Control Organisation (DCGI-CDSCO) to initiate Phase I/II human clinical trials for its Covid-19 (plasmid DNA) vaccine. The company has completed preclinical development and plans to begin the trials in July 2020, it said.
In animal studies, the vaccine was found to
